Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

Objective:Rasagiline, a monoamine oxidase type B inhibitor, is indicated for both the initial treatment of Parkinson disease (PD) and as adjunctive (add-on) treatment for patients already taking dopaminergic therapy. This open-label prospective community-based clinical trial was designed to determin